Executive leadership at ACTUATE THERAPEUTICS.
Board of directors at ACTUATE THERAPEUTICS.
Research analysts covering ACTUATE THERAPEUTICS.
Recent press releases and 8-K filings for ACTU.
Actuate Therapeutics Reports Positive Follow-Up Data from Phase 2 Trial for Metastatic Pancreatic Cancer
ACTU
- Actuate Therapeutics, Inc. announced positive follow-up data from its randomized controlled Phase 2 trial (Actuate 1801-Part 3B) for elraglusib plus gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic cancer.
- The study met its primary endpoint, demonstrating statistically significant improved overall survival with the elraglusib combination, which reduced the risk of death by 38% compared to GnP alone.
- Key efficacy results include a median overall survival of 10.1 months for elraglusib/GnP versus 7.2 months for GnP alone, and the 24-month survival rate increased fivefold to 12.9% in the elraglusib/GnP arm compared to 2.6% in the GnP arm.
- The safety and tolerability profile of elraglusib was consistent with previously reported data, with serious treatment-emergent adverse events (TEAE) similar between the elraglusib/GnP (56.1%) and GnP alone (56.4%) arms.
5 days ago
Actuate Therapeutics Enters $100 Million At-The-Market Equity Offering Agreement
ACTU
- Actuate Therapeutics, Inc. entered into an At the Market Issuance Sales Agreement on November 28, 2025, enabling the company to offer and sell shares of its common stock with an aggregate offering price of up to $100,000,000.
- The sales will be conducted through B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC, who will act as sales agents and receive a commission of up to 3.0% of the gross sales proceeds.
- As of November 28, 2025, the aggregate market value of the company's outstanding voting and non-voting common equity held by non-affiliates was approximately $77.5 million.
Nov 28, 2025, 10:21 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more